FDA Panel's 8-6 Vote Opens Door for Peptide-Fueled Telehealth Boom
A narrow FDA advisory panel vote to ease peptide compounding restrictions could trigger a rapid expansion of telehealth-delivered wellness treatments, despite a stark lack of safety data. With HHS Secretary RFK Jr. supporting access, healthcare providers must prepare for a new era of direct-to-consumer peptide therapies.